Breaking News Instant updates and real-time market news.

NK

NantKwest

$1.13

0.105 (10.24%)

14:52
06/03/19
06/03
14:52
06/03/19
14:52

NantKwest launches Phase 1 trial of CD19 t-haNK cell therapy in lymphoma

NantKwest announced that the company's t-haNK investigational new drug application has cleared FDA review and the program has now transitioned to a first-in-human clinical trial targeting CD19 t-haNK in advanced B-cell lymphoma. "Based on extensive and encouraging preclinical results, we have enhanced our ability to modularly combine this proprietary off-the-shelf t-haNK-based therapy with a wide range of monoclonal antibodies using this multi-targeted approach. We are now ready to transition this innovation in NK cell based therapeutics to a Phase I human clinical trials designed to assess the safety, tolerability and efficacy of CD19 t-haNK cell therapy in advanced b-cell lymphoma. Upon completion of the safety phase, NantKwest intends to combine this CD19 t-haNK cell therapy with other synergistic, immunomodulatory agents as part of an integrative, combination therapy approach that we describe as the NANT Cancer Vaccine to further enhance the synergistic effectiveness of this novel therapeutic intervention," said CEO Patrick Soon-Shiong.

  • 04

    Jun

  • 06

    Jun

NK NantKwest
$1.13

0.105 (10.24%)

10/17/18
SBSH
10/17/18
DOWNGRADE
Target $3
SBSH
Sell
Citi downgrades NantKwest to Sell on 'unwarranted' recent rally
Citi analyst Joel Beatty last night downgraded NantKwest to Sell from Neutral with an unchanged price target of $3. The analyst views the recent rally in the shares as "unwarranted" since he's not aware of any change in fundamentals. Beatty points out that NantKwest has a history of missing its own timelines for vaccine studies.
11/30/18
SBSH
11/30/18
UPGRADE
Target $2
SBSH
Neutral
NantKwest upgraded to Neutral from Sell at Citi
Citi analyst Joel Beatty upgraded NantKwest to Neutral while lowering his price target for the shares to $2 from $3. The analyst cites valuation for the upgrade following the recent pullback in the shares.
05/30/19
SBSH
05/30/19
DOWNGRADE
SBSH
Sell
NantKwest downgraded to Sell from Neutral at Citi
05/31/19
SBSH
05/31/19
DOWNGRADE
Target $0.8
SBSH
Sell
Citi downgrades NantKwest to Sell with 80c price target
Citi analyst Joel Beatty last night downgraded NantKwest to Sell from Neutral and cut his price target for the shares to 80c from $1.25. The analyst believes the most likely scenario is that NantKwest's pipeline shows "little signs of progress" over the next 12 months, while continuing operating cash burn. Clinical trial activity involving the company's agents may be decreasing, at least temporarily, Beatty tells investors in a research note.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.